Neuphoria Therapeutics Inc. Increase (Decrease) in Accounts Receivable
Neuphoria Therapeutics Inc. (NEUP) reported Increase (Decrease) in Accounts Receivable of $801.48 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-09-18
- Neuphoria Therapeutics Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$791.91K.
- Neuphoria Therapeutics Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $495.43K.
- Neuphoria Therapeutics Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $1.11M.
- Neuphoria Therapeutics Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$10.19K.
- Neuphoria Therapeutics Inc. increase (decrease) in accounts receivable for fiscal 2026 was $801.48K.
- Neuphoria Therapeutics Inc. increase (decrease) in accounts receivable for fiscal 2025 was -$114.94K.
- Neuphoria Therapeutics Inc. increase (decrease) in accounts receivable for fiscal 2024 was -$299.20K.
- Neuphoria Therapeutics Inc. increase (decrease) in accounts receivable for fiscal 2023 was -$4.14M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$791.91K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | -$296.48K derived: sum of 2 quarters · filed 2026-09-18 | $811.67K derived: sum of 3 quarters · filed 2026-09-18 | $801.48K 10-K · filed 2026-09-18 |
| 2026-03-31 | $495.43K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | $1.60M derived: sum of 2 quarters · filed 2026-05-15 | $1.59M 10-Q · filed 2026-05-15 | $1.58M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-12-31 | $1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | $1.10M 10-Q · filed 2026-02-17 | $1.09M derived: sum of 3 quarters · filed 2026-09-18 | $1.07M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-09-30 | -$10.19K 10-Q · filed 2025-11-14 | -$22.83K derived: sum of 2 quarters · filed 2026-09-18 | -$33.80K derived: sum of 3 quarters · filed 2026-09-18 | -$114.20K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-06-30 | -$12.64K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | -$23.61K derived: sum of 2 quarters · filed 2026-09-18 | -$104.01K derived: sum of 3 quarters · filed 2026-09-18 | -$114.94K 10-K · filed 2026-09-18 |
| 2025-03-31 | -$10.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | -$91.37K derived: sum of 2 quarters · filed 2026-05-15 | -$102.29K 10-Q · filed 2026-05-15 | -$81.11K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$80.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$91.32K 10-Q · filed 2026-02-17 | -$70.15K derived: sum of 3 quarters · filed 2026-02-17 | -$79.79K derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | -$10.92K 10-Q · filed 2025-11-14 | $10.25K derived: sum of 2 quarters · filed 2025-11-14 | $613.00 derived: sum of 3 quarters · filed 2025-11-14 | -$326.38K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $21.18K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $11.54K derived: sum of 2 quarters · filed 2025-09-29 | -$315.45K derived: sum of 3 quarters · filed 2025-09-29 | -$299.20K 10-K · filed 2025-09-29 |
| 2024-03-31 | -$9.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-20 | -$336.63K derived: sum of 2 quarters · filed 2025-05-20 | -$320.38K 10-Q · filed 2025-05-20 | |
| 2023-12-31 | -$326.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | -$310.74K 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | $16.25K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$4.14M 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |